

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
08/591,651	08/591,651 02/12/1996		JOHN B. CLASSEN	CLASSEN=1A	9417	
1444	7590 12/13/2006			EXAMINER		
		EIMARK, P.L.L.C.	SALVOZA, M FRANCO G			
624 NINTH SUITE 300	STREET	, NW	ART UNIT	PAPER NUMBER		
WASHING	ron, do	20001-5303	1648			
				DATE MAILED: 12/13/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	Application No. Applicant(s)						
	Office Action Commons	08/591,69	51	CLASSEN, JOHN B.					
	Office Action Summary	Examiner	,	Art Unit					
		M. Franco		1648					
Period fo	The MAILING DATE of this communicationr Reply	n appears on the	cover sheet with	the correspondence a	ddress				
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILIN asions of time may be available under the provisions of 37 C SIX (6) MONTHS from the mailing date of this communication period for reply is specified above, the maximum statutory pre to reply within the set or extended period for reply will, by reply received by the Office later than three months after the end patent term adjustment. See 37 CFR 1.704(b).	NG DATE OF THE FR 1.136(a). In no even on. period will apply and w statute, cause the app	HIS COMMUNICA ent, however, may a rep ill expire SIX (6) MONTH lication to become ABAI	ATION.  ly be timely filed  HS from the mailing date of this NDONED (35 U.S.C. § 133).					
Status									
1)[X]	Responsive to communication(s) filed on	03 November 2	004						
2a)□	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.								
3)	, <del></del>								
-,-	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims		.,.,						
<u>-</u>		anding in the on	nliantion						
-	Claim(s) <u>See Continuation Sheet</u> is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.								
	Claim(s) is/are allowed.								
· · · · · · · · · · · · · · · · · · ·	Claim(s) is/are rejected.								
7)	Claim(s) is/are objected to.			•					
8)	Claim(s) <u>266-303</u> are subject to restriction	and/or election	requirement						
, —	•	rand/or election	requirement.						
Applicati	on Papers								
· · · · · ·	The specification is objected to by the Exa								
10)	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.								
	Applicant may not request that any objection t	=	•	, ,					
	Replacement drawing sheet(s) including the c			·					
11)	The oath or declaration is objected to by the	he Examiner. No	te the attached (	Office Action or form P	TO-152.				
Priority ι	ınder 35 U.S.C. § 119				•				
12)	Acknowledgment is made of a claim for fo	reign priority un	der 35 U.S.C. § 1	119(a)-(d) or (f).	•				
	a) ☐ All b) ☐ Some * c) ☐ None of:								
•	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the		• •	· · · · · · · · · · · · · · · · · · ·	ıl Stage				
	application from the International B	•			J				
* 5	See the attached detailed Office action for	a list of the certi	fied copies not re	eceived.					
•									
Attachmen	t(s)								
	e of References Cited (PTO-892)		4) Interview Sur	mmary (PTO-413)					
	e of Draftsperson's Patent Drawing Review (PTO-94	Mail Date							
	nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date		6) Other:	ormal Patent Application					

Continuation of Disposition of Claims: Claims pending in the application are 5,6,8,10,11,16,27-30,32-41,43,44,46,49,52,55-57,59-68,71-74,77-88,90-112,115-128,144-152,259 and 266-303.

Application/Control Number: 08/591,651

Art Unit: 1648

## **DETAILED ACTION**

New claims 266-303 have been added. It was determined that upon further consideration that further restriction is appropriate for a thorough and complete examination. The Office regrets any inconvenience.

## Election/Restrictions

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. 4. As indicated in the previous Restriction, the inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: each of the Groups comprises a separate method for the use of the claimed kits. While the Applicant is entitled to claims directed to a first method of using the claimed compositions, the separate methods are not considered to share a common special technical feature.

The species are as follows:

1. One type of immunogenic agent must be elected as recited in claims 268-276; 284-291.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Application/Control Number: 08/591,651

Art Unit: 1648

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

A. Claim 267 requires one species (monovalent, divalent, trivalent, etc.) of immunogenic agent.

The following new claim(s) are generic: 266, 267, 277-283, 292-303.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: In the instant case, the inventions as claimed lack the same or corresponding technical features by reciting separate immunogenic agents having distinct valencies, distinct structures, and distinct physical, chemical characteristics requiring separate searches of the prior art. Furthermore, the inventions as claimed do not encompass overlapping subject matter and there is nothing of record to show them to be obvious variants. See MPEP § 1850.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and

Art Unit: 1648

specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to M. Franco Salvoza whose telephone number is (571) 272-8410. The examiner can normally be reached on M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 08/591,651

Art Unit: 1648

Page 5

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

M. Franco Salvoza Patent Examiner

BRUCE R. CAMPELL, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

Bure Compell